MTOR and depressive disorder: Ketamine’s antianhedonic effect is an active area of investigation considering that preclinical studies suggest a synergistic effect of ketamine and lithium, highlighting activation of the mTOR pathway and GSK-3 inhibition, thus improving both depression–anhedonia and suicidality [40].